BIOMAT Database Logo BIOMAT Database Logo

Molecular studies of chronic myelogenous leukemia using the polymerase chain reaction. 1991

K Nakamura, and T Miyashita, and M Ozaki, and M Iwaya, and S Nakazawa, and J Okamura, and N Kamada, and K Tanaka, and N Kobayashi, and S Mizutani
Department of Virology, National Children's Medical Research Center, Tokyo, Japan.

Thirty-two cases of chronic myelogenous leukemia (CML) were studied to determine whether there was a correlation between the position of the chromosome breakpoint within the breakpoint cluster region (bcr) on chromosome 22 and the type of chimeric mRNA expression. One case with the chromosome breakpoint in zone 2 of the major bcr (Mbcr) and six cases with breakpoints in zone 3 expressed Mbcr exon 2-abl (b2-a) mRNA, and they were in distinguishable at the level of mRNA expression. The remaining ten cases with breakpoints in zone 3 and all ten cases with breakpoints in zone 4 expressed Mbcr exon 3-abl (b3-a) mRNA with or without b2-a mRNA. Three cases with breakpoints in zone 5 expressed b3-a mRNA, and none of these expressed Mbcr exon 4-abl(b4-a) mRNA. The cases with breakpoints in zones 4 or 5 had b3-a mRNA expression indistinguishable from those with breakpoints in zone 3. In two patients, the breakpoint in the bcr could not be determined by Southern hybridization using the 3' bcr probe or the large bcr probe. However, when analyzed for chimeric mRNA expression, both of them exhibited b3-a chimeric mRNA, suggesting the possibility that the entire Mbcr is deleted in the majority of leukemic cells in these patients. These studies indicate that Southern hybridization analysis combined with the polymerase chain reaction assay is a useful approach to understanding the pathologic role of bcr-abl gene recombination and expression in the development of CML.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002869 Chromosome Aberrations Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS. Autosome Abnormalities,Cytogenetic Aberrations,Abnormalities, Autosome,Abnormalities, Chromosomal,Abnormalities, Chromosome,Chromosomal Aberrations,Chromosome Abnormalities,Cytogenetic Abnormalities,Aberration, Chromosomal,Aberration, Chromosome,Aberration, Cytogenetic,Aberrations, Chromosomal,Aberrations, Chromosome,Aberrations, Cytogenetic,Abnormalities, Cytogenetic,Abnormality, Autosome,Abnormality, Chromosomal,Abnormality, Chromosome,Abnormality, Cytogenetic,Autosome Abnormality,Chromosomal Aberration,Chromosomal Abnormalities,Chromosomal Abnormality,Chromosome Aberration,Chromosome Abnormality,Cytogenetic Aberration,Cytogenetic Abnormality
D005091 Exons The parts of a transcript of a split GENE remaining after the INTRONS are removed. They are spliced together to become a MESSENGER RNA or other functional RNA. Mini-Exon,Exon,Mini Exon,Mini-Exons
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

K Nakamura, and T Miyashita, and M Ozaki, and M Iwaya, and S Nakazawa, and J Okamura, and N Kamada, and K Tanaka, and N Kobayashi, and S Mizutani
Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction.
January 1990, Proceedings of the National Academy of Sciences of the United States of America,
K Nakamura, and T Miyashita, and M Ozaki, and M Iwaya, and S Nakazawa, and J Okamura, and N Kamada, and K Tanaka, and N Kobayashi, and S Mizutani
Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction.
June 1992, Leukemia,
K Nakamura, and T Miyashita, and M Ozaki, and M Iwaya, and S Nakazawa, and J Okamura, and N Kamada, and K Tanaka, and N Kobayashi, and S Mizutani
Reverse transcriptase-polymerase chain reaction for bcr/abl fusion in chronic myelogenous leukemia.
June 1996, American journal of clinical pathology,
K Nakamura, and T Miyashita, and M Ozaki, and M Iwaya, and S Nakazawa, and J Okamura, and N Kamada, and K Tanaka, and N Kobayashi, and S Mizutani
Detection of bcr-abl fusion mRNA in chronic myelogenous leukemia by reverse transcription polymerase chain reaction using nested primers.
June 1993, Osaka city medical journal,
K Nakamura, and T Miyashita, and M Ozaki, and M Iwaya, and S Nakazawa, and J Okamura, and N Kamada, and K Tanaka, and N Kobayashi, and S Mizutani
The molecular pathogenesis of avian leukemia virus infections using the polymerase chain reaction.
January 1990, Developments in biological standardization,
K Nakamura, and T Miyashita, and M Ozaki, and M Iwaya, and S Nakazawa, and J Okamura, and N Kamada, and K Tanaka, and N Kobayashi, and S Mizutani
Monitoring the efficiency of interferon-alpha therapy in chronic myelogenous leukemia (CML) patients by competitive polymerase chain reaction.
April 1997, Leukemia,
K Nakamura, and T Miyashita, and M Ozaki, and M Iwaya, and S Nakazawa, and J Okamura, and N Kamada, and K Tanaka, and N Kobayashi, and S Mizutani
Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity.
April 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
K Nakamura, and T Miyashita, and M Ozaki, and M Iwaya, and S Nakazawa, and J Okamura, and N Kamada, and K Tanaka, and N Kobayashi, and S Mizutani
Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction and clinical decision making.
August 1999, Blood,
K Nakamura, and T Miyashita, and M Ozaki, and M Iwaya, and S Nakazawa, and J Okamura, and N Kamada, and K Tanaka, and N Kobayashi, and S Mizutani
Analysis of clonality at the level of progenitors in chronic myelogenous leukaemia using the polymerase chain reaction.
January 1992, Leukemia research,
K Nakamura, and T Miyashita, and M Ozaki, and M Iwaya, and S Nakazawa, and J Okamura, and N Kamada, and K Tanaka, and N Kobayashi, and S Mizutani
Detection of Philadelphia chromosome-positive cells by the polymerase chain reaction following bone marrow transplant for chronic myelogenous leukemia.
August 1989, Blood,
Copied contents to your clipboard!